布仑妥昔单抗维多汀
医学
CD30
蕈样真菌病
内科学
中性粒细胞减少症
间变性大细胞淋巴瘤
淋巴瘤
切碎
环磷酰胺
蒽环类
侵袭性淋巴瘤
不利影响
肿瘤科
胃肠病学
化疗
美罗华
癌症
乳腺癌
作者
Emmanuel Ribereau-Gayon,Marie Donzel,Félix Pham,Nicolas Romain-Scelle,Marie Perier‐Muzet,B. Balme,Alexandra Traverse‐Glehen,Hervé Ghesquières,Stéphane Dalle
标识
DOI:10.1080/10428194.2023.2216820
摘要
Aggressive CD30-positive cutaneous T-cell lymphomas (CD30+CTCL) are associated with unfavorable prognosis. Anthracycline-based polychemotherapy (CHOP) and brentuximab-vedotin (BV) monotherapy are related to poor outcomes in case of extracutaneous involvement or rapidly-progressing disease. Our objective was to assess the effectiveness of BV + CHP in aggressive CD30+CTCL. We included 7 patients treated with BV + CHP from April 2015 to January 2022: 4 had mycosis fungoides with large-cell transformation, 2 had primary cutaneous anaplastic large-cell lymphoma, and 1 harbored a primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphoma. After a median [IQR] follow-up of 17.2 [13.2–21.0] months, 6/7 patients achieved an ORR lasting ≥4 months. The median [IQR] duration of response was 9.5 [5.9–11.1] months and the median [IQR] progression free survival was 14.9 [11.6–16.4] months. Four patients displayed progression with a median (range) time to next treatment of 15.8 (6.5–16.3) months. Two grade-3 adverse events were reported: febrile neutropenia and thromboembolic event. BV + CHP displayed substantial antitumor activity and favorable safety profile in 7 patients with aggressive CD30+CTCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI